Will UnitedHealth Stock Recover?
Shares of embattled health insurance giant UnitedHealth (NYSE:UNH) plummeted by…
Sell
27
RARE Quote, Financials, Valuation and Earnings
Last price:
$21.27
Seasonality move
:
-0.92%
Day range:
$22.93 - $24.35
52-week range:
$18.41 - $46.27
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
3.64x
P/B ratio:
247.54x
Volume:
1.9M
Avg. volume:
2.7M
1-year change:
-45.89%
Market cap:
$2.3B
Revenue:
$560.2M
EPS (TTM):
-$5.94
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
RARE
Ultragenyx Pharmaceutical, Inc.
|
$201.9M | -$1.17 | 23.49% | -12.37% | $64.00 |
|
APLS
Apellis Pharmaceuticals, Inc.
|
$199.3M | -$0.40 | 15.96% | -35.6% | $33.95 |
|
CORT
Corcept Therapeutics, Inc.
|
$254.9M | $0.30 | 27.74% | -71.78% | $84.00 |
|
CRMD
CorMedix, Inc.
|
$127M | $0.81 | 178.58% | 96.01% | $14.86 |
|
INSM
Insmed, Inc.
|
$264M | -$1.16 | 192.54% | -43.17% | $215.15 |
|
JNJ
Johnson & Johnson
|
$24.1B | $2.46 | 7.79% | -40.82% | $231.25 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
RARE
Ultragenyx Pharmaceutical, Inc.
|
$23.50 | $64.00 | $2.3B | -- | $0.00 | 0% | 3.64x |
|
APLS
Apellis Pharmaceuticals, Inc.
|
$22.05 | $33.95 | $2.8B | 74.24x | $0.00 | 0% | 2.74x |
|
CORT
Corcept Therapeutics, Inc.
|
$38.34 | $84.00 | $4B | 43.81x | $0.00 | 0% | 6.18x |
|
CRMD
CorMedix, Inc.
|
$7.36 | $14.86 | $579.9M | 3.58x | $0.00 | 0% | 2.48x |
|
INSM
Insmed, Inc.
|
$146.17 | $215.15 | $31.2B | -- | $0.00 | 0% | 62.20x |
|
JNJ
Johnson & Johnson
|
$244.55 | $231.25 | $589.2B | 22.14x | $1.30 | 2.1% | 6.30x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
RARE
Ultragenyx Pharmaceutical, Inc.
|
98.95% | 0.914 | 29.68% | 1.61x |
|
APLS
Apellis Pharmaceuticals, Inc.
|
54.23% | 0.668 | 16.61% | 2.96x |
|
CORT
Corcept Therapeutics, Inc.
|
1% | -3.733 | 0.07% | 2.85x |
|
CRMD
CorMedix, Inc.
|
1.16% | 2.679 | 0.48% | 1.60x |
|
INSM
Insmed, Inc.
|
44.07% | 2.488 | 2.43% | 4.18x |
|
JNJ
Johnson & Johnson
|
37.69% | -0.049 | 9.89% | 0.69x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
RARE
Ultragenyx Pharmaceutical, Inc.
|
$123.3M | -$170.9M | -53.69% | -307.83% | -106.85% | -$92.7M |
|
APLS
Apellis Pharmaceuticals, Inc.
|
$433.7M | $223.2M | 6.35% | 18.94% | 48.67% | $108.3M |
|
CORT
Corcept Therapeutics, Inc.
|
$203M | $10.2M | 15.84% | 16% | 4.92% | $54.5M |
|
CRMD
CorMedix, Inc.
|
$93.1M | $51.3M | 94.54% | 95.25% | 49.24% | $30.4M |
|
INSM
Insmed, Inc.
|
$111.4M | -$261.4M | -70.98% | -193.23% | -183.61% | -$222.2M |
|
JNJ
Johnson & Johnson
|
$16.4B | $5.4B | 21.45% | 34.46% | 21.9% | $5.9B |
Ultragenyx Pharmaceutical, Inc. vs. Competitors
-
Which has Higher Returns RARE or APLS?
Apellis Pharmaceuticals, Inc. has a net margin of -112.81% compared to Ultragenyx Pharmaceutical, Inc.'s net margin of 47.04%. Ultragenyx Pharmaceutical, Inc.'s return on equity of -307.83% beat Apellis Pharmaceuticals, Inc.'s return on equity of 18.94%.
Company Gross Margin Earnings Per Share Invested Capital RAREUltragenyx Pharmaceutical, Inc.77.12% -$1.81 $879.3M APLSApellis Pharmaceuticals, Inc.94.58% $1.66 $876.5M -
What do Analysts Say About RARE or APLS?
Ultragenyx Pharmaceutical, Inc. has a consensus price target of $64.00, signalling upside risk potential of 172.34%. On the other hand Apellis Pharmaceuticals, Inc. has an analysts' consensus of $33.95 which suggests that it could grow by 53.96%. Given that Ultragenyx Pharmaceutical, Inc. has higher upside potential than Apellis Pharmaceuticals, Inc., analysts believe Ultragenyx Pharmaceutical, Inc. is more attractive than Apellis Pharmaceuticals, Inc..
Company Buy Ratings Hold Ratings Sell Ratings RAREUltragenyx Pharmaceutical, Inc.15 1 0 APLSApellis Pharmaceuticals, Inc.11 7 1 -
Is RARE or APLS More Risky?
Ultragenyx Pharmaceutical, Inc. has a beta of 0.161, which suggesting that the stock is 83.893% less volatile than S&P 500. In comparison Apellis Pharmaceuticals, Inc. has a beta of 0.256, suggesting its less volatile than the S&P 500 by 74.354%.
-
Which is a Better Dividend Stock RARE or APLS?
Ultragenyx Pharmaceutical, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Apellis Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Ultragenyx Pharmaceutical, Inc. pays -- of its earnings as a dividend. Apellis Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios RARE or APLS?
Ultragenyx Pharmaceutical, Inc. quarterly revenues are $159.9M, which are smaller than Apellis Pharmaceuticals, Inc. quarterly revenues of $458.6M. Ultragenyx Pharmaceutical, Inc.'s net income of -$180.4M is lower than Apellis Pharmaceuticals, Inc.'s net income of $215.7M. Notably, Ultragenyx Pharmaceutical, Inc.'s price-to-earnings ratio is -- while Apellis Pharmaceuticals, Inc.'s PE ratio is 74.24x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Ultragenyx Pharmaceutical, Inc. is 3.64x versus 2.74x for Apellis Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income RAREUltragenyx Pharmaceutical, Inc.3.64x -- $159.9M -$180.4M APLSApellis Pharmaceuticals, Inc.2.74x 74.24x $458.6M $215.7M
-
Which has Higher Returns RARE or CORT?
Corcept Therapeutics, Inc. has a net margin of -112.81% compared to Ultragenyx Pharmaceutical, Inc.'s net margin of 9.32%. Ultragenyx Pharmaceutical, Inc.'s return on equity of -307.83% beat Corcept Therapeutics, Inc.'s return on equity of 16%.
Company Gross Margin Earnings Per Share Invested Capital RAREUltragenyx Pharmaceutical, Inc.77.12% -$1.81 $879.3M CORTCorcept Therapeutics, Inc.97.79% $0.16 $638.3M -
What do Analysts Say About RARE or CORT?
Ultragenyx Pharmaceutical, Inc. has a consensus price target of $64.00, signalling upside risk potential of 172.34%. On the other hand Corcept Therapeutics, Inc. has an analysts' consensus of $84.00 which suggests that it could grow by 119.09%. Given that Ultragenyx Pharmaceutical, Inc. has higher upside potential than Corcept Therapeutics, Inc., analysts believe Ultragenyx Pharmaceutical, Inc. is more attractive than Corcept Therapeutics, Inc..
Company Buy Ratings Hold Ratings Sell Ratings RAREUltragenyx Pharmaceutical, Inc.15 1 0 CORTCorcept Therapeutics, Inc.3 1 1 -
Is RARE or CORT More Risky?
Ultragenyx Pharmaceutical, Inc. has a beta of 0.161, which suggesting that the stock is 83.893% less volatile than S&P 500. In comparison Corcept Therapeutics, Inc. has a beta of 0.247, suggesting its less volatile than the S&P 500 by 75.347%.
-
Which is a Better Dividend Stock RARE or CORT?
Ultragenyx Pharmaceutical, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Corcept Therapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Ultragenyx Pharmaceutical, Inc. pays -- of its earnings as a dividend. Corcept Therapeutics, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios RARE or CORT?
Ultragenyx Pharmaceutical, Inc. quarterly revenues are $159.9M, which are smaller than Corcept Therapeutics, Inc. quarterly revenues of $207.6M. Ultragenyx Pharmaceutical, Inc.'s net income of -$180.4M is lower than Corcept Therapeutics, Inc.'s net income of $19.4M. Notably, Ultragenyx Pharmaceutical, Inc.'s price-to-earnings ratio is -- while Corcept Therapeutics, Inc.'s PE ratio is 43.81x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Ultragenyx Pharmaceutical, Inc. is 3.64x versus 6.18x for Corcept Therapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income RAREUltragenyx Pharmaceutical, Inc.3.64x -- $159.9M -$180.4M CORTCorcept Therapeutics, Inc.6.18x 43.81x $207.6M $19.4M
-
Which has Higher Returns RARE or CRMD?
CorMedix, Inc. has a net margin of -112.81% compared to Ultragenyx Pharmaceutical, Inc.'s net margin of 49.9%. Ultragenyx Pharmaceutical, Inc.'s return on equity of -307.83% beat CorMedix, Inc.'s return on equity of 95.25%.
Company Gross Margin Earnings Per Share Invested Capital RAREUltragenyx Pharmaceutical, Inc.77.12% -$1.81 $879.3M CRMDCorMedix, Inc.89.26% $1.26 $378.5M -
What do Analysts Say About RARE or CRMD?
Ultragenyx Pharmaceutical, Inc. has a consensus price target of $64.00, signalling upside risk potential of 172.34%. On the other hand CorMedix, Inc. has an analysts' consensus of $14.86 which suggests that it could grow by 101.86%. Given that Ultragenyx Pharmaceutical, Inc. has higher upside potential than CorMedix, Inc., analysts believe Ultragenyx Pharmaceutical, Inc. is more attractive than CorMedix, Inc..
Company Buy Ratings Hold Ratings Sell Ratings RAREUltragenyx Pharmaceutical, Inc.15 1 0 CRMDCorMedix, Inc.4 0 0 -
Is RARE or CRMD More Risky?
Ultragenyx Pharmaceutical, Inc. has a beta of 0.161, which suggesting that the stock is 83.893% less volatile than S&P 500. In comparison CorMedix, Inc. has a beta of 1.388, suggesting its more volatile than the S&P 500 by 38.76%.
-
Which is a Better Dividend Stock RARE or CRMD?
Ultragenyx Pharmaceutical, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. CorMedix, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Ultragenyx Pharmaceutical, Inc. pays -- of its earnings as a dividend. CorMedix, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios RARE or CRMD?
Ultragenyx Pharmaceutical, Inc. quarterly revenues are $159.9M, which are larger than CorMedix, Inc. quarterly revenues of $104.3M. Ultragenyx Pharmaceutical, Inc.'s net income of -$180.4M is lower than CorMedix, Inc.'s net income of $108.6M. Notably, Ultragenyx Pharmaceutical, Inc.'s price-to-earnings ratio is -- while CorMedix, Inc.'s PE ratio is 3.58x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Ultragenyx Pharmaceutical, Inc. is 3.64x versus 2.48x for CorMedix, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income RAREUltragenyx Pharmaceutical, Inc.3.64x -- $159.9M -$180.4M CRMDCorMedix, Inc.2.48x 3.58x $104.3M $108.6M
-
Which has Higher Returns RARE or INSM?
Insmed, Inc. has a net margin of -112.81% compared to Ultragenyx Pharmaceutical, Inc.'s net margin of -259.95%. Ultragenyx Pharmaceutical, Inc.'s return on equity of -307.83% beat Insmed, Inc.'s return on equity of -193.23%.
Company Gross Margin Earnings Per Share Invested Capital RAREUltragenyx Pharmaceutical, Inc.77.12% -$1.81 $879.3M INSMInsmed, Inc.78.29% -$1.75 $1.7B -
What do Analysts Say About RARE or INSM?
Ultragenyx Pharmaceutical, Inc. has a consensus price target of $64.00, signalling upside risk potential of 172.34%. On the other hand Insmed, Inc. has an analysts' consensus of $215.15 which suggests that it could grow by 47.19%. Given that Ultragenyx Pharmaceutical, Inc. has higher upside potential than Insmed, Inc., analysts believe Ultragenyx Pharmaceutical, Inc. is more attractive than Insmed, Inc..
Company Buy Ratings Hold Ratings Sell Ratings RAREUltragenyx Pharmaceutical, Inc.15 1 0 INSMInsmed, Inc.18 1 0 -
Is RARE or INSM More Risky?
Ultragenyx Pharmaceutical, Inc. has a beta of 0.161, which suggesting that the stock is 83.893% less volatile than S&P 500. In comparison Insmed, Inc. has a beta of 1.105, suggesting its more volatile than the S&P 500 by 10.538%.
-
Which is a Better Dividend Stock RARE or INSM?
Ultragenyx Pharmaceutical, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Insmed, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Ultragenyx Pharmaceutical, Inc. pays -- of its earnings as a dividend. Insmed, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios RARE or INSM?
Ultragenyx Pharmaceutical, Inc. quarterly revenues are $159.9M, which are larger than Insmed, Inc. quarterly revenues of $142.3M. Ultragenyx Pharmaceutical, Inc.'s net income of -$180.4M is higher than Insmed, Inc.'s net income of -$370M. Notably, Ultragenyx Pharmaceutical, Inc.'s price-to-earnings ratio is -- while Insmed, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Ultragenyx Pharmaceutical, Inc. is 3.64x versus 62.20x for Insmed, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income RAREUltragenyx Pharmaceutical, Inc.3.64x -- $159.9M -$180.4M INSMInsmed, Inc.62.20x -- $142.3M -$370M
-
Which has Higher Returns RARE or JNJ?
Johnson & Johnson has a net margin of -112.81% compared to Ultragenyx Pharmaceutical, Inc.'s net margin of 20.83%. Ultragenyx Pharmaceutical, Inc.'s return on equity of -307.83% beat Johnson & Johnson's return on equity of 34.46%.
Company Gross Margin Earnings Per Share Invested Capital RAREUltragenyx Pharmaceutical, Inc.77.12% -$1.81 $879.3M JNJJohnson & Johnson66.77% $2.10 $130.9B -
What do Analysts Say About RARE or JNJ?
Ultragenyx Pharmaceutical, Inc. has a consensus price target of $64.00, signalling upside risk potential of 172.34%. On the other hand Johnson & Johnson has an analysts' consensus of $231.25 which suggests that it could fall by -5.44%. Given that Ultragenyx Pharmaceutical, Inc. has higher upside potential than Johnson & Johnson, analysts believe Ultragenyx Pharmaceutical, Inc. is more attractive than Johnson & Johnson.
Company Buy Ratings Hold Ratings Sell Ratings RAREUltragenyx Pharmaceutical, Inc.15 1 0 JNJJohnson & Johnson9 10 0 -
Is RARE or JNJ More Risky?
Ultragenyx Pharmaceutical, Inc. has a beta of 0.161, which suggesting that the stock is 83.893% less volatile than S&P 500. In comparison Johnson & Johnson has a beta of 0.350, suggesting its less volatile than the S&P 500 by 64.977%.
-
Which is a Better Dividend Stock RARE or JNJ?
Ultragenyx Pharmaceutical, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Johnson & Johnson offers a yield of 2.1% to investors and pays a quarterly dividend of $1.30 per share. Ultragenyx Pharmaceutical, Inc. pays -- of its earnings as a dividend. Johnson & Johnson pays out 46.59% of its earnings as a dividend. Johnson & Johnson's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios RARE or JNJ?
Ultragenyx Pharmaceutical, Inc. quarterly revenues are $159.9M, which are smaller than Johnson & Johnson quarterly revenues of $24.6B. Ultragenyx Pharmaceutical, Inc.'s net income of -$180.4M is lower than Johnson & Johnson's net income of $5.1B. Notably, Ultragenyx Pharmaceutical, Inc.'s price-to-earnings ratio is -- while Johnson & Johnson's PE ratio is 22.14x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Ultragenyx Pharmaceutical, Inc. is 3.64x versus 6.30x for Johnson & Johnson. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income RAREUltragenyx Pharmaceutical, Inc.3.64x -- $159.9M -$180.4M JNJJohnson & Johnson6.30x 22.14x $24.6B $5.1B
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is Lumentum The Best Laser Stock to Buy?
Though certainly less well-known than the huge tech businesses that…
Is Planet Fitness Stock Undervalued?
Planet Fitness (NYSE:PLNT) has had a difficult 12 months, retreating…
Stock Ideas
Buy
54
Is NVDA Stock a Buy?
Market Cap: $4.5T
P/E Ratio: 64x
Sell
46
Is AAPL Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 35x
Sell
42
Is GOOG Stock a Buy?
Market Cap: $3.7T
P/E Ratio: 29x
Alerts
Sell
17
ICLR alert for Feb 13
ICON plc [ICLR] is up 18.97% over the past day.
Buy
67
CGNX alert for Feb 13
Cognex Corp. [CGNX] is up 1.41% over the past day.
Buy
77
IPGP alert for Feb 13
IPG Photonics Corp. [IPGP] is up 3.35% over the past day.
